For the six months ended June 30, 2025, YD Biopharma reported net revenue of $204.0 million, a decrease of $21.0 million, or 9%, compared to $225.0 million in the prior year period. The decline in net revenue was attributed to a change in product mix. The top five products accounted for 56% of total revenue during the period. Keytruda injection generated $42.5 million in revenue, Exolens Hioxifilcon contact lenses generated $35.0 million, and Faslodex Solution for injection generated $14.2 million. The subtotal for the top five products was $128.3 million. Cost of revenue decreased by $20.7 million, or 13%, to $135.2 million from $155.9 million a year earlier, reflecting the reduction in net revenue. Gross profit remained unchanged at $69.0 million for both the six months ended June 30, 2025, and the comparative period in 2024. Operating expenses totaled $2.0 million for the six months ended June 30, 2025, up from $262,264 in the prior period, primarily due to $1.0 million in general and administrative fees related to expansion and restructuring, and $0.8 million in research and development expenses for licensed patents and know-how. Net loss was $1.9 million for the six months ended June 30, 2025, compared to $0.17 million in the prior period, mainly due to higher professional and consultancy fees associated with the business combination with Breeze Holdings, increased R&D expenses, and staff costs linked to business expansion. Cash and cash equivalents, including unrestricted cash with maturities of three months or less, were $469,520 as of June 30, 2025, down from $3.13 million at December 31, 2024, primarily due to general and administrative expenses and R&D spending. YD Biopharma advanced ocular therapies through a 3D Global license for corneal mesenchymal stem cells and exosomes, supporting an IRB-approved corneal specimen study at Shuang-Ho Hospital. Clinical trial applications were initiated for exosome-based contact lenses and artificial tears for dry eye in 2025. The company also expanded into oncology diagnostics via EG BioMed, securing patents, technology, and U.S. market authorization for pancreatic cancer methylation detection in June 2024.